Avast Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing first-in-class, non-invasive peptide therapeutics to treat neurodegenerative diseases, including Parkinson’s and Alzheimer’s.
Founded by University of Kentucky neuroscientists, Avast holds an exclusive license to a proprietary collection of small peptides capable of:
TPM Research is addressing a long-standing gap in hospital patient care: the transition from bed to chair, lab, bathroom, or vehicle.
For nearly 90 years, the standard solution has been the traditional collapsible wheelchair with its well-known limitations. The Care Continuum Chair changes that with innovative features that deliver superior clinical, aesthetic, and financial outcomes.
PHIOGEN is a pre-clinical-stage biotechnology company developing first-in-class immunizing therapeutics designed to both treat drug-resistant infections and induce durable immune protection against recurrence, with a focus on chronic conditions.
Cervu is developing an innovative at-home pelvic health trainer system that combines a hardware device that features multiple functionalities with a mobile app to deliver personalized care for women seeking to improve their pelvic health.
Imagine Devices Inc. is revolutionizing neonatal and pediatric critical care with a safer, smarter approach to monitoring premature infants.
Each year, over 13 million premature infants are admitted to Neonatal Intensive Care Units (NICUs) worldwide, connected to more than 20 wires, tubes, and sensors for feeding, respiratory support, and vital signs. Conventional systems create serious risks—including nasal and skin injuries, infections, respiratory complications, and high clinical workload.
Postpartum hemorrhage remains the leading cause of maternal deaths worldwide and in the U.S., where maternal mortality rates are the highest among developed nations.
This preventable condition costs the U.S. healthcare system $1.8 billion annually, with studies showing up to 90% of deaths are avoidable.
